Apr 18 |
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
|
Apr 2 |
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
|
Mar 15 |
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
|
Mar 10 |
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|
Mar 8 |
Oncternal Therapeutics files for mixed shelf offering
|
Mar 8 |
Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Oncternal Therapeutics GAAP EPS of -$3.11 misses by $0.03, revenue of $0.3M beats by $0.16M
|
Mar 7 |
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Mar 6 |
Oncternal Therapeutics Q4 2023 Earnings Preview
|